Equities

Inmode Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Inmode Ltd

Actions
Health CareMedical Equipment and Services
  • Price (USD)14.24
  • Today's Change-0.38 / -2.60%
  • Shares traded1.65m
  • 1 Year change-23.36%
  • Beta2.1751
Data delayed at least 15 minutes, as of Feb 11 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.

  • Revenue in USD (TTM)364.49m
  • Net income in USD149.58m
  • Incorporated2008
  • Employees599.00
  • Location
    Inmode LtdTavor Building, Sha'ar Yokneam, Pob 533YOKNEAM 2069200IsraelISR
  • Phone+972 49097470
  • Websitehttps://inmodemd.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Embecta Corp1.08bn139.50m609.37m1.85k4.35--3.360.56442.372.3718.31-10.350.97572.276.35583,621.6012.6116.6916.6022.6563.1766.7412.9215.711.873.181.7913.07-3.80-0.103321.84-25.93-26.03--
Tactile Systems Technology Inc311.51m18.17m618.03m1.04k35.623.0224.821.980.77680.776813.289.181.148.388.07300,398.306.641.297.721.5549.8749.125.831.263.20--0.000.006.769.11-40.529.10-15.97--
Alpha Tau Medical Ltd0.00-39.97m627.54m125.00--8.09-----0.5212-0.52120.000.90990.00----0.00-40.90-34.28-44.43-36.47------------0.0735-------8.89--11.60--
Beta Bionics Inc88.57m-77.84m650.68m404.00--2.21--7.35-2.07-2.072.216.700.41492.548.16304,364.30-36.46---40.57--54.51---87.89--9.83--0.00--442.93---24.17------
Bioventus Inc563.83m7.82m667.90m950.0071.844.0211.641.180.11230.11238.392.010.76661.954.47606,267.801.31-6.291.89-8.4967.7667.401.71-12.071.141.730.616--11.8911.0065.33---15.55--
SI-Bone Inc193.58m-21.76m668.23m349.00--3.87--3.45-0.5113-0.51134.553.980.83931.297.53554,664.80-9.43-24.17-10.61-26.8779.6282.72-11.24-40.936.62--0.1711--20.3719.9628.67--33.83--
Avanos Medical Inc699.90m-468.60m683.29m2.23k--0.8782--0.9763-10.18-10.1815.0916.760.51392.145.76314,279.30-34.41-4.82-39.66-5.4252.2854.01-66.95-11.321.368.920.1167--2.15-0.2826-3,802.02---18.86--
CeriBell Inc82.81m-52.46m771.22m281.00--4.69--9.31-1.45-1.452.294.430.67171.546.36294,708.20-42.55---48.06--87.99---63.35--12.25-29.420.1074--44.71---37.30------
Integra Lifesciences Holdings Corp1.64bn-495.34m855.26m4.40k--0.8237--0.5206-6.46-6.4621.4513.330.42611.526.34373,741.10-12.852.90-15.393.2557.2162.59-30.157.141.802.680.63830.004.471.20-110.25---3.19--
STAAR Surgical Co230.59m-96.37m860.54m1.16k--2.41--3.73-1.96-1.964.647.170.4641.292.80199,300.80-19.393.81-22.264.4273.8777.03-41.795.424.35--0.000.00-2.6415.89-194.66--18.11--
Butterfly Network Inc88.45m-79.87m861.37m190.00--4.22--9.74-0.3347-0.33470.37290.80710.31860.74093.93465,515.80-28.77---34.57--43.24---90.31-190.033.56--0.00--24.52--45.78------
Inmode Ltd364.49m149.58m924.12m599.006.791.416.152.542.152.155.3910.340.46771.199.24608,504.2019.1928.0521.1531.2878.8283.3941.0440.998.71--0.000.00-19.7620.35-8.4124.28-0.7024--
Castle Biosciences Inc343.53m-12.24m944.84m761.00--2.0230.952.75-0.4533-0.453311.6716.020.63779.056.89451,419.20-2.27-6.95-2.50-7.5279.9480.76-3.56-17.496.31--0.0218--51.0944.97131.7543.5797.74--
BioLife Solutions Inc88.83m-13.99m1.09bn159.00--3.07--12.28-0.2922-0.0611.877.370.22960.88756.18558,698.10-3.62-1.92-3.92-2.1070.0252.54-15.75-9.063.64--0.0207--8.4424.6238.27--19.15--
Novocure Ltd642.27m-177.65m1.17bn1.49k--3.43--1.83-1.61-1.615.813.050.49734.018.43431,632.40-13.75-9.61-33.14-11.8475.5777.57-27.66-19.321.50--0.6887--18.8211.4918.55--32.52--
Data as of Feb 11 2026. Currency figures normalised to Inmode Ltd's reporting currency: US Dollar USD

Institutional shareholders

23.47%Per cent of shares held by top holders
HolderShares% Held
DOMA Perpetual Capital Management LLCas of 30 Sep 20252.84m4.49%
Renaissance Technologies LLCas of 30 Sep 20252.45m3.88%
Acadian Asset Management LLCas of 30 Sep 20251.98m3.13%
BlackRock Fund Advisorsas of 30 Sep 20251.63m2.58%
Systematic Financial Management LPas of 30 Sep 20251.14m1.80%
Cooper Creek Partners Management LLCas of 30 Sep 20251.01m1.59%
Meitav Mutual Funds Ltd.as of 30 Sep 2025976.89k1.55%
Ancient Art LPas of 30 Sep 2025956.63k1.51%
Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 2025955.74k1.51%
Harel Mutual Funds Ltd.as of 31 Dec 2025899.99k1.42%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.